ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoantibodies"

  • Abstract Number: 163 • 2020 Pediatric Rheumatology Symposium

    Anti-Dense Fine Speckled (DFS) Autoantibodies in Autoinflammatory Vasculopathies

    Asa Laestadius1, May Choi 1, Marvin Fritzler 1, Aurore Fifi-Mah 2, Susanne Benseler 3 and Joao Dantas 1, 1University of Calgary, Calgary, Canada, 2Calgary, Canada, 3Univeristy of Calgary, Calagry, Canada

    Background/Purpose: Autoantibodies to dense fine speckles 70 (DFS70) is now recognized to be more common among apparently healthy individuals compared to patients with ANA-related rheumatic…
  • Abstract Number: 020 • 2020 Pediatric Rheumatology Symposium

    Murine Roseolovirus Induces Autoimmune Disease and Development of Autoantibodies

    Tarin Bigley1 and Wayne Yokoyama 2, 1Washington University in St. Louis, Saint Louis, Missouri, 2Washington University in St. Louis, St Louis, Missouri

    Background/Purpose: Murine roseolovirus (MRV) is a recently sequenced beta-herpesvirus that is a natural murine pathogen and is genetically highly related to HHV6 and HHV7. The…
  • Abstract Number: 054 • 2020 Pediatric Rheumatology Symposium

    Clinical and Laboratory Characteristics in Juvenile-onset Systemic Lupus Erythematosus Across Age Groups

    Joseph Massias 1, Eve Smith 1, Michael Beresford 1 and Christian Hedrich1, 1University of Liverpool, Liverpool, United Kingdom

    Background/Purpose: Systemic lupus erythematous (SLE) is a systemic autoimmune/inflammatory condition. Up to 20% of patients develop symptoms before their 18th birthday and are diagnosed with…
  • Abstract Number: 1774 • 2019 ACR/ARP Annual Meeting

    Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis

    Izumi Kurata1, Isao Matsumoto 1, Natsuko Mikami 1, Ayako Ohyama 1, Atsumu Osada 1, Yuya Kondo 1, Hiroto Tsuboi 1 and Takayuki Sumida 1, 1Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose: Recently, IL-23-Th17 cells axis and hyposialylation of antibodies were proved to be linked to experimental and rheumatoid arthritis. However it remains uncertain how Tfh,…
  • Abstract Number: 47 • 2019 ACR/ARP Annual Meeting

    Autoreactivity to Acetylated Histones Defines a Subset of RA Patients and Is Associated with Acetyl – Citrulline Anti-Modified Protein Autoantibody (AMPA) Cross-Reactivity

    Peter Sahlström 1, Lisa Liljefors 1, Vijay Joshua 2, Natalia Sherina 1, Radha Thyagarajan 1, Lena Israelsson 2, Ragnhild Stålesen 2, Monika Hansson 3, Khaled Amara 2, Ulf Reimer 4, Leonid Padyukov 1, Elisabet Svenungsson 5, Karin Lundberg 1, Anca Catrina 3, Lars Klareskog 3, Vivianne Malmström 2 and Caroline Grönwall2, 1Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, 3Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 4JPT Peptide Technologies, Berlin, Germany, 5Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Serum anti-citrullinated protein autoantibodies (ACPA) in rheumatoid arthritis (RA) display reactivity to a variety of cit-autoantigens. Studies of human ACPA mAbs have revealed that…
  • Abstract Number: 1868 • 2019 ACR/ARP Annual Meeting

    Clinical Correlations of Autoantibodies Against Heat Shock Cognate 71 kDa Protein in Patients with Juvenile Dermatomyositis

    Rie Karasawa1, James N. Jarvis 2, Toshiko Sato 1, Megumi Tanaka 1, Mark Hicar 2, Kazuo Yudoh 1, Terrance O’Hanlon 3, Payam Noroozi-Farhadi 3 and Lisa G. Rider 4, 1Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, 2University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, 3NIEHS, NIH, Bethesda, MD, 4Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD

    Background/Purpose: Juvenile dermatomyositis (JDM) is an inflammatory myopathy characterized by prominent vascular and perivascular inflammation in affected skeletal muscles. The mechanisms of vessel injury in…
  • Abstract Number: 80 • 2019 ACR/ARP Annual Meeting

    The Role of Adopter Protein SH3BP2 in a Murine Systemic Lupus Erythematosus Model

    Kyoko Kawahara1, Tomoyuki Mukai 2, Akiko Nagasu 1, Masanori Iseki 3, Hajime Nagasu 4, Shoko Tshuji 1, Takahiko Akagi 1, Yasuyoshi Ueki 5 and Yoshitaka Morita 1, 1Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Japan, 2Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Okayama, Japan, 3Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, 4Department of Nephrology and Hypertension, Kawasaki medical School, Kurashiki, Okayama, Japan, 5Department of Biomedical Sciences and Comprehensive Care Indiana University School of Dentistry, Indianapolis, IN

    Background/Purpose: An adaptor protein SH3BP2 (Src homology 3 domain-binding protein 2) is widely expressed in immune cells and controls intracellular signaling pathways, such as Syk,…
  • Abstract Number: 1900 • 2019 ACR/ARP Annual Meeting

    Assessing Commercial Titers of anti-Ro60 and Ro52 Antibodies to Risk Stratify Surveillance of Anti-Ro/SSA Antibody Positive Pregnancies

    Kimberly Robins 1, Rohit Bhan1, Catherine Trad 1, Rebecca Cohen 1, Miao Chang 1, Benjamin Wainwright 1, Mala Masson 1, Shilpi Mehta-Lee 1, Peter Izmirly 1, Robert Clancy 1, Bettina Cuneo 2 and Jill Buyon 1, 1NYU School of Medicine, New York, 2Children's Hospital Colorado, Aurora

    Background/Purpose: Pregnancy counseling of all anti-Ro positive women includes advice regarding the development of congenital heart block (CHB), albeit the risk is only 2% for…
  • Abstract Number: 126 • 2019 ACR/ARP Annual Meeting

    Antibodies Targeting Mitochondrial Antigens Are Associated with Reduced Thrombotic Events in APS

    Yann Becker1, Anne-Sophie Julien 2, Alexandra Godbout 3, Éric Boilard 3 and Paul Fortin 4, 1Département de microbiologie et immunologie, Centre de recherche du CHU de Québec - Université Laval, Canada, Quebec, QC, Canada, 2Service de consultation statistique (SCS). Département de mathématiques et de statistique, Québec, QC, Canada, 3Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Québec, Qc, Canada, Québec, QC, Canada, 4Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada

    Background/Purpose: Mitochondria are intracellular organelles involved in many biological pathways such as energy supply by oxidative phosphorylation and apoptosis. Mitochondria are considered as derived from…
  • Abstract Number: 2003 • 2019 ACR/ARP Annual Meeting

    Anti-Polygalacturonic Acid Antibody (PGA-Ab) Induced Bone Destruction in Rheumatoid Arthritis by Promoting Osteoclastogenesis via Integrin Beta 5

    JIAWEI XIE1 and HUI DAI 1, 1Peking University, Beijing, China (People's Republic)

    Background/Purpose: Anti-polygalacturonic acid antibody (PGA-Ab) is a new rheumatoid arthritis (RA)-related autoantibody first identified by our group. The sensitivity and specificity of PGA-Ab is even…
  • Abstract Number: 402 • 2019 ACR/ARP Annual Meeting

    Chronic Disease Course and IVIg-dependance in Long-term Follow-up of Anti-HMGCR Immune-mediated Necrotizing Myopathy

    Océane Landon-Cardinal1, Kuberaka Mariampillai 2, Céline Anquetil 3, Aude Rigolet 2, Baptiste Hervier 4, Nicolas Champtiaux 2, Olivier Benveniste 3 and Yves Allenbach 3, 1Centre Hospitalier de l'Université de Montréal, Montréal, Canada, 2Pitié-Salpêtrière University Hospital, Paris, France, 3Sorbonne Université, Paris, France, 4Hopital Pitie-Salpetriere, Paris, France

    Background/Purpose: Anti-HMGCR antibodies have been associated with a severe form of immune-mediated necrotizing myopathy (IMNM) with a poor muscle strength recovery and early muscle damage.…
  • Abstract Number: 2020 • 2019 ACR/ARP Annual Meeting

    Metabolic Changes Induced by Anti-Malondialdehyde Antibodies Promote Osteoclast Development

    Koji Sakurabas1, Akilan Krishnamurthy 2, Cheng Xu 3, Khaled Amara 4, Vivianne Malmström 4, Sergiu-Bogdan Catrina 3, Caroline Grönwall 4, Bence Rethi 5 and Anca Catrina 6, 1Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, stockholm, Sweden, 2Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, Stockholm, 3Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 4Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, 5Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, 6Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden

    Background/Purpose: Malondialdehyde (MDA) is highly reactive compound produced by lipid-peroxidation in situations associated with oxidative stress. MDA can irreversibly modify proteins (e.g. lysine, arginine and histidine…
  • Abstract Number: 455 • 2019 ACR/ARP Annual Meeting

    Anti-Protein-Arginine Deiminase (PAD) 4 IgA Are Present in the Sera of Rheumatoid Arthritis Patients and Are Associated with Joint Erosion and Biological Treatment Use

    Laura Martinez-Prat1, Victor Manuel Martínez Taboada 2, Marcos Lopez-Hoyos 3 and Michael Mahler 4, 1Inova Diagnostics, Francisco de Vitoria University, San Diego, CA, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Cantabria, Spain, 4Inova Diagnostics, San Diego, CA

    Background/Purpose: Over the past years, novel biomarkers have been described in rheumatoid arthritis (RA) patients, including autoantibodies to the protein-arginine deiminase (PAD) enzymes. Anti-PAD4 IgG…
  • Abstract Number: 2039 • 2019 ACR/ARP Annual Meeting

    High Prevalence and Disease Correlation of Autoantibodies Against p40 Encoded by Long Interspersed Nuclear Elements (LINE-1) in SLE

    Kennedy Ukadike1, Victoria Carter 1, John LaCava 2, Martin Taylor 3, Anders Bengtsson 4, Christian Lood 1 and Tomas Mustelin 1, 1University of Washington, Seattle, WA, 2The Rockefeller University, New York, NY, 3Massachusetts General Hospital, Boston, MA, 4Lund University, Lund, Sweden

    Background/Purpose: The long interspersed nuclear element 1 (LINE-1) has two major open reading frames (ORFs): ORF1 encodes the RNA-binding p40 protein, and ORF2 encodes the…
  • Abstract Number: 646 • 2019 ACR/ARP Annual Meeting

    A Meta-Analysis of Anti-Ribosomal P Autoantibodies in Systemic Lupus Erythematosus: A Misunderstood Autoantibody

    May Choi1, Rachael Brown 2, Katherine Buhler 3, Michael Mahler 4 and Marvin Fritzler 1, 1Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2University of Victoria, Victoria, Canada, 3University of Calgary, Calgary, Canada, 4Inova Diagnostics, San Diego, CA

    Background/Purpose: Anti-ribosomal P (Rib-P) antibodies have become known as a highly specific biomarker for the diagnosis of SLE and potentially a biomarker for neuropsychiatric SLE…
  • 1
  • 2
  • 3
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology